Congratulations, MB! Crossing fingers for you. Our 3 month supply is being Fed Exed as I type this message. Insurance was a SNAP! Doctors did NOT wait for a 3 month appointment...our clinic initiated the whole process. Less than 2 weeks from order to shipping...like we hit the "EASY" button.
Sentiment: Strong Buy
Vertex should get Orkambi approval by Monday or sooner, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff said he is confident that the FDA will approve Vertex's Orkambi in homozygous F508del cystic fibrosis by its PDUFA date of July 5, meaning a decision should come by either late Thursday or by Monday morning, due to the holiday. Pricing will be key, Tenthoff noted, adding that he expects it to be in-line with Kalydeco's $311,000, except with steeper gross-to-net discounts. Tenthoff expects Vertex to retain its dominance of CF therapy and keeps his Overweight rating and $146 target on its shares, which closed down $4.84 near $122 yesterday.
Galapagos and AbbVie are working together to develop a triple combination therapy for cystic fibrosis patients with the Class II (F508del) mutation. Novel potentiator GLPG1837 is currently in Phase 1 and is expected to enter a Phase 2 study in class III mutation patients before end 2015. Novel corrector GLPG2222 is expected to enter Phase 1 before end 2015. Galapagos and AbbVie expect to nominate a second novel corrector by Q3 2015 and thereby complete the triple combination therapy discovery phase. This second novel corrector is expected to enter Phase 1 in Q2 2016
It will be interesting to see how Proteostasis and Nivalis (N30) start to factor into the third leg on the stool equation. Their therapies might improve Orkambi and Kalydeco.
Not that the FDA is sentimental but June 24th is the 1 year anniversary of the Kalydeco/Lumacaftor phase III trial results. Could be as good as any day for a thumbs up!
Verty's got it right (been lurking). - most won't see the positive in this release but that's not my problem & VRTX management shouldn't care either. Remember...to a CF patient or parent...all we want is to arrest the disease; To [theoretically] stop the lung related affects of CF in its tracks. Which, for a growing # of CF-ers, is what VRTX science delivers. Trust me...if I could halt my kids lung function at 87%...I'd take it and RUN! The only other option is to watch these patients is to get sicker and sicker by the day - right before your eyes. Last part of my rant...VRTX has the corrector/potentiator market until at least 2022 and IMO, once K + Lumacaftor revenues come in, they will be active buyers.
Utterly fantastic win for VRTX today & for CF patients - a huge win/win! Arguments over pricing are ridiculous. VRTX CF drugs REDUCE the of CF patient care costs, a fact Insurance companies admit. Vertex and their investors will enjoy many years of happy returns...until another company comes along with a better drug that's safer and cheaper. The soonest that will be is 2022. Just incredible news for biopharma innovation...
More and more players in CF nowadays! Never enough me! The following is from their web site..."Our lead product Resunab™ is a novel oral anti-inflammatory drug that is expected to commence Phase IIa clinical trials for the treatment of cystic fibrosis and scleroderma, pending U.S. Food and Drug Administration (FDA) approval in the second half of 2014."